Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026
Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026
Company Deals

Siemens Healthineers and Cleveland Clinic Announce 10-Year Strategic Partnership

Fineline Cube Aug 4, 2026
Company Deals

Apeloa Pharmaceutical and METiS Therapeutics Announce Strategic CDMO Partnership

Fineline Cube Aug 4, 2026
Drug Medical Device Policy / Regulatory

NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics

Fineline Cube Aug 4, 2026
Company Drug

Leads Biolabs’ Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership

Fineline Cube Aug 5, 2026
Company Drug

Allergan Aesthetics’ BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication

Fineline Cube Aug 5, 2026
Company Deals

XtalPi Partners with CTTQ for AI-Driven Small-Molecule Drug Development

Fineline Cube Dec 9, 2022

Sino-US artificial intelligence (AI) firm XtalPi Inc. struck a partnership with China-based Jiangsu Chia Tai...

Company Drug

Harbour BioMed Concludes Phase I Study for HBM4003 in Advanced Melanoma

Fineline Cube Dec 9, 2022

Harbour BioMed (HBM; HKG: 2142), a biotech operating out of the United States, the Netherlands,...

Company Deals

Frontier Biotechnologies Partners with Yuyue Med for FB2001 Atomizer

Fineline Cube Dec 9, 2022

China-based Frontier Biotechnologies Inc. (SHA: 688221) announced a strategic collaboration agreement with compatriot firm Jiangsu...

Company Deals

Harbour BioMed’s Nona Biosciences Licenses Antibody Platform to Kelun-Biotech

Fineline Cube Dec 9, 2022

Harbour BioMed (HKG: 2142), a biotech operating out of the Netherlands, the United States, and...

Company Deals

ExoNeuglia Secures Angel Funding for iPSC-Based Cell Therapy

Fineline Cube Dec 8, 2022

ExoNeuglia, a stem-cell-focused biotech based in Suzhou, reportedly raised “tens of millions” of renminbi in...

Company Drug

Jacobio’s KRAS G12C Inhibitor JAB-21822 Receives Breakthrough Therapy Designation

Fineline Cube Dec 8, 2022

The Center for Drug Evaluation (CDE) website indicates that China-based Jacobio Pharmaceuticals Group Co., Ltd’s...

Company Drug

CSPC and Ascletis Get NMPA Approval for COVID-19 Drug Clinical Trials

Fineline Cube Dec 8, 2022

China-based firms CSPC Pharmaceutical Group Ltd (HKG: 1093) and Ascletis Pharma Inc. (HKG: 1672) both...

Policy / Regulatory

24 Provinces Form Alliances for Volume-Based Procurement of Medical Consumables

Fineline Cube Dec 8, 2022

The Henan provincial alliance procurement office released a notification indicating that 24 provinces/regions will form...

Company Deals

Yuanmai Cell Biotechnology Secures Angel Funding for Macrophage Immunotherapy

Fineline Cube Dec 8, 2022

Yuanmai Cell Biotechnology Co., Ltd, a macrophage immunotherapy developer based in Nanjing, reportedly raised “tens...

Company Deals

Yantai Dongcheng Pharma Acquires Rights to 18F-APN-1607 from Aprinoia Therapeutics

Fineline Cube Dec 8, 2022

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) announced the plan to acquire the...

Company Deals

Shanghai Hantong Medtech Raises Angel Funding for Ultrasound Platform

Fineline Cube Dec 8, 2022

Shanghai Hantong Medical Technology Co., Ltd reportedly raised “tens of millions” of renminbi in an...

Company Deals

GenAssist Therapeutics Secures Series A Funding for Gene Therapy Development

Fineline Cube Dec 8, 2022

China’s Suzhou GenAssist Therapeutics Co., Ltd, a base editing technology-based gene therapy developer, reportedly raised...

Company Drug

Hansoh’s Generic Firazyr Approved for Marketing in China by NMPA

Fineline Cube Dec 8, 2022

The National Medical Products Administration (NMPA) website indicates that China-based Hansoh Pharmaceutical Group Co., Ltd’s...

Company Drug

NMPA Approves Viatris’ Symfi Lo for HIV-1 Treatment in China

Fineline Cube Dec 8, 2022

The National Medical Products Administration (NMPA) website indicates that US-based Viatris Inc.’s (NASDAQ: VTRS) Symfi...

Company Drug

SciClone’s Danyelza Approved for Marketing in China by NMPA

Fineline Cube Dec 8, 2022

The National Medical Products Administration (NMPA) website indicates that SciClone Pharmaceuticals Inc’s (Nasdaq: SCLN) Danyelza...

Company Drug

Enhertu Confirmed as New Standard of Care for Breast Cancer in Phase III Study

Fineline Cube Dec 8, 2022

AstraZeneca PLC (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) released the latest data supporting the...

Company Deals

Shaanxi Panlong Pharma Partners with Porton Pharma Solutions for Drug Development

Fineline Cube Dec 7, 2022

China-based Shaanxi Panlong Pharmaceutical Group Co., Ltd (SHE: 002864) announced a technology commission (development) agreement...

Company Deals

Akeso’s Ivonescimab Secures Record-Breaking Out-License Deal with Summit Therapeutics

Fineline Cube Dec 7, 2022

A new bar was set for the most valuable out-license deal struck by a China-based...

Company Deals

Qihui Biopharmaceuticals Raises Series A Funding for Microbubbles Technology

Fineline Cube Dec 7, 2022

Beijing Qihui Biopharmaceuticals Co., Ltd reportedly raised “tens of millions” of renminbi in a Series...

Company Deals

Westgene Biopharma Secures RMB 150M Series A Financing for mRNA Drug Development

Fineline Cube Dec 7, 2022

Westgene Biopharma, an mRNA drug developer based in Chengdu, reportedly raised RMB 150 million (USD...

Posts pagination

1 … 627 628 629 … 704

Recent updates

  • Leads Biolabs’ Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership
  • Amgen Reports Q2 2026 Revenue of $10.05B, Driven by 26% Growth in Core Portfolio Despite Denosumab Decline
  • Allergan Aesthetics’ BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication
  • Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance
  • Sino Biopharmaceutical’s BCL-2 Inhibitor TQB3909 Tablet Receives CDE Acceptance for CLL/SLL Treatment in Relapsed/Refractory Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Leads Biolabs’ Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership

Company

Amgen Reports Q2 2026 Revenue of $10.05B, Driven by 26% Growth in Core Portfolio Despite Denosumab Decline

Company Drug

Allergan Aesthetics’ BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication

Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.